Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Insider Analysis From Nishith Desai Associates: Learning and Unlearning from Section 3(d) Of The Indian Patents Act (Part 1 of 2)

This article was originally published in PharmAsia News

Executive Summary

By Milind Antani and Gowree Gokhale, Nishith Desai Associates, Mumbai, Indi

You may also be interested in...



Supreme Court Judge Recused From Glivec Patent Case In India

MUMBAI - A strongly worded letter of appeal signed by prominent IP lawyers and health activists to India's minister of law and Justice Salman Khurshid led to the surprise recusal of Supreme Court Judge Dalveer Bhandari from the controversial and long-pending Glivec (imatinib) patentability case in India

Supreme Court Judge Recused From Glivec Patent Case In India

MUMBAI - A strongly worded letter of appeal signed by prominent IP lawyers and health activists to India's minister of law and Justice Salman Khurshid led to the surprise recusal of Supreme Court Judge Dalveer Bhandari from the controversial and long-pending Glivec (imatinib) patentability case in India

Stage Set For India To Frame Compulsory Licensing Provisions As Contrasting Groups Make Their Case

The Department of Industrial Policy and Promotion is analyzing and interpreting comments on a contentious subject that has kept Indian and multinational drug firms bitterly divided for more than five years, while forcing the government into a dilemma over an acceptable policy.

Related Content

UsernamePublicRestriction

Register

WI965023

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel